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Objectives The aim of the current Valve Academic Research Consortium (VARC)-2 initiative was to revisit the selection and
definitions of transcatheter aortic valve implantation (TAVI) clinical endpoints to make them more suitable to the
present and future needs of clinical trials. In addition, this document is intended to expand the understanding of
patient risk stratification and case selection.
Background A recent study confirmed that VARC definitions have already been incorporated into clinical and research prac-
tice and represent a new standard for consistency in reporting clinical outcomes of patients with symptomatic
severe aortic stenosis (AS) undergoing TAVI. However, as the clinical experience with this technology has ma-
tured and expanded, certain definitions have become unsuitable or ambiguous.
Methods and
Results
Two in-person meetings (held in September 2011 in Washington, DC, USA, and in February 2012 in Rotterdam, the
Netherlands) involving VARC study group members, independent experts (including surgeons, interventional and non-
interventional cardiologists, imaging specialists, neurologists, geriatric specialists, and clinical trialists), the US Food
and Drug Administration (FDA), and industry representatives, provided much of the substantive discussion from which
this VARC-2 consensus manuscript was derived. This document provides an overview of risk assessment and patient
stratification that need to be considered for accurate patient inclusion in studies. Working groups were assigned to
define the following clinical endpoints: mortality, stroke, myocardial infarction, bleeding complications, acute kidney
injury, vascular complications, conduction disturbances and arrhythmias, and a miscellaneous category including rele-
vant complications not previously categorized. Furthermore, comprehensive echocardiography recommendations are
provided for the evaluation of prosthetic valve (dys)function. Definitions for the quality of life assessments are also
reported. These endpoints formed the basis for several recommended composite endpoints.
Conclusions This VARC-2 document has provided further standardization of endpoint definitions for studies evaluating the
use of TAVI, which will lead to improved comparability and interpretability of the study results, supplying an in-
creasingly growing body of evidence with respect to TAVI and/or surgical aortic valve replacement. This initiative
and document can furthermore be used as a model during current endeavors of applying definitions to other
transcatheter valve therapies (for example, mitral valve repair). (J Am Coll Cardiol 2012;60:1438–54) © 2012
by the American College of Cardiology Foundation
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The first Valve Academic Research Consortium (VARC)
consensus manuscript was published in January 2011 with
the goal of achieving consensus for (i) selecting appropriate
clinical endpoints reflecting device, procedure and patient-
related effectiveness and safety, and (ii) standardizing defi-
nitions for single and composite clinical endpoints, for trans-
catheter aortic valve implantation (TAVI) clinical trials
(1,2). A recent pooled analysis, which included 3,519
patients from 16 unique studies, confirms that VARC
definitions have already been incorporated into clinical and
research practice and represent a new standard for consis-
tency in reporting clinical outcomes of patients with symp-
tomatic severe aortic stenosis (AS) undergoing TAVI (3).
However, as the clinical experience with this technology has
matured and expanded, certain definitions have become
unsuitable or ambiguous (3–7). The aim of the current
VARC was therefore to revisit the selection and definitions
of TAVI-related clinical endpoints to make them more
suitable to the present and future needs of clinical trials. In
addition, this document is intended to expand the under-
standing of patient risk stratification and case selection.
Similar to the VARC-1 process, two in-person meet-
ings (held in September 2011 in Washington, DC, USA,
and in February 2012 in Rotterdam, the Netherlands)
involving VARC study group members, independent
experts (including surgeons, interventional and non-
interventional cardiologists, imaging specialists, neurolo-
gists, geriatric specialists, and clinical trialists), the US
Food and Drug Administration (FDA), and industry
representatives, provided much of the substantive discus-Figure 1 Porcelain Aorta or Severely Atherosclerotic Aortasion from which this VARC-2 consensus manuscript was
derived (see Appendixes).
Risk Scores and Comorbidities
Risk stratification of patients is crucial to identifying appro-
priate candidates for specific cardiac procedures. The Eu-
roSCORE and Society of Thoracic Surgeons (STS) score
are the most widely used risk scores to predict operative
mortality in cardiac surgery. These models were developed
and validated in a standard surgical risk population. The
predictive power of both models is therefore suboptimal in
high-risk patients with valvular disease, although the STS
score has shown to outperform the Logistic EuroSCORE
(8). These models are even more limited in application to
patients who are considered at prohibitive risk for cardiac
surgery, a cohort that could particularly benefit from TAVI.
Current models could be improved by the addition of
specific clinical and anatomical variables that affect mortality
(9). As an example, the presence of a porcelain aorta and
frailty are important factors not included in either risk
model but are routinely considered during patient evaluation
(Fig. 1, Table 1).
Perhaps the most important patient characteristic not
included in current risk models is frailty (10). Frailty is
frequently assessed subjectively based upon an informal
‘eyeball test’. However, physical performance assessments
such as gait speed and grip strength are more objective
performance measures that may capture an individual’s
overall functional status (11). These continuous measures
are reproducible and can be re-assessed at various time
points. In addition, they require no language translation.
Assessments of cognition, weight (loss), activity level, and
1).
ormali
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tional information on the overall health state of the indi-
vidual (11). These limitations are more often found in
patients with a high comorbidity burden and may co-exist
with certain laboratory findings (e.g. low serum albumin,
elevated inflammatory markers, anemia) that further reflect
the health state and physiological reserve of the frail patient.
Baseline evaluation of the presence of cognitive dysfunc-
tion (mild cognitive impairment or dementia) has also
emerged as an essential part of the initial risk stratification,
especially in older populations, where the risk, benefit, and
Risk factors Not Captured by Traditional Risk ScoresTable 1 Risk factors Not Captured by Traditional Risk Scores
Comorbidities
Porcelain aorta or severely atherosclerotic
aorta
Heavy circumferential calcifica
ascending aorta extending
feasible
Frailty Slowness, weakness, exhausti
inactivity, loss of independe
Criteria:
5 m walking time*
Grip strength*
BMI 20 kg/m2 and/or we
Serum albumin 3.5 g/dL
Cognitive impairment or de
Severe liver disease/cirrhosis Any of the following:
Child-Pugh class C
MELD score 10
Portal-caval, spleno-renal, o
Biopsy proven cirrhosis with
Hostile chest Any of the following or other r
sternotomy or right anterio
Abnormal chest wall anatom
abnormalities (including
Complications from prior su
Evidence of severe radiation
muscle loss, lung fibrosi
History of multiple recurren
IMA or other critical conduit(s) crossing midline
and/or adherent to posterior table of
sternum
A patent IMA graft that is adh
re-operation is likely. A pat
the following are present:
The conduit(s) are radiograp
of the sternum.
The conduit(s) are radiograp
the sternum but lie with
Severe pulmonary hypertension
Severe right ventricular dysfunction
Primary or secondary pulmona
than two-thirds of systemic
Criteria as defined by the guid
20 cm2, etc.)†
*Variable with respect to age and gender without validated scientific thresholds. †Rudski et al. (7
CT  computed tomography; MELD  Model for End-Stage Liver Disease; INR  international ncost-effectiveness of invasive procedures must be weighedjudiciously. Pre-procedural cognitive assessment may also
help avoid attributing post-procedural mental status
changes to stroke categories. Among the several clinically
established rating scales [e.g. Mini-Mental State Examina-
tion, modified Telephone Interview of Cognitive Status
(TICS-M), Clinical Dementia Rating Scale] (12), there is
no particular standard for TAVI. Nevertheless, some sys-
tematic cognitive assessment by neuropsychological experts
should be a part of the initial heart team evaluation.
Table 1 provides an overview of these and other risk
factors (Figs. 1 to 3) and VARC-2 recommendations on
ition/Criteria Diagnostic Modalities
r severe atheromatous plaques of the entire
arch such that aortic cross-clamping is not
Non-contrast axial CT at levels:
Sinotubular junction
Tubular ascending aorta
between the sinotubular
junction and the
innominate artery
Innominate artery
Entire transverse arch
sting and malnutrition, poor endurance and
ss 5 kg/year
Medical history
Physical examination
Physical performance measures
Cognitive assessments
Laboratory tests
jugular intrahepatic portal shunt
l hypertension or hepatocellular dysfunction
Medical history
Physical examination
Laboratory tests
Child-Pugh classification
MELD score
Liver biopsy
that make redo operation through
cotomy prohibitively hazardous:
to severe kyphoscoliosis or other skeletal
oplasty, Potts’ disease)
ge (e.g. skin burns, bone destruction,
sophageal stricture)
al effusions causing internal adhesions
Medical history
Physical examination
Chest X-ray
CT scan
o the sternum such that injuring it during
ay be considered at extreme risk if any of
indistinguishable from the posterior table
distinguishable from the posterior table of
mm of the posterior table
Axial CT scan images illustrating
the graft crossing the midline
so that the distance from
sternum to graft can be
measured.
Angiogram from the lateral and
PA projections and/or a
CPRorVR (volume rendering)
3D reconstructed CT scan
image showing relationships
between the graft and the
sternum
ertension with PA systolic pressures greater
re
(e.g. TAPSE 15 mm, RV end-systolic area
Echocardiography, right and left-
heart-catheterization
documenting PA and
systemic pressures
Documentation of secondary
causes of pulmonary
hypertension
zed ratio; IMA  internal mammary artery; PA  pulmonary artery.Defin
tion o
to the
on, wa
nce
ight lo
mentia
r trans
porta
easons
r thora
y due
thorac
rgery
dama
s, or oe
t pleur
erent t
ient m
hically
hically
in 2–3
ry hyp
pressu
elineshow each should be assessed. In clinical trials, it will be
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risk and to standardize the evaluation criteria and process.
This will help to determine which subsets of patients are
likely to benefit from TAVI treatment.
Patient Stratification: The Heart Team Approach
Valve Academic Research Consortium-2 recommends the
use of a heart team for patient evaluation. The heart team
should consist of at least (interventional) cardiologists,
cardiovascular surgeons, and imaging specialists, but its
Figure 2 Hostile ChestFigure 3 Patent IMA Graft Crossing Midline and/or Adherent to thecomposition is dynamic and can also include anesthesiolo-
gists, geriatricians, neurologists, etc. This multi-disciplinary
team should convene as a group on a regular basis to review and
interpret clinical data to arrive at a consensus on the optimal
treatment strategy for each patient. The heart team approach
also allows for the adjustment of the decision-making process
according to local experience and circumstances.
The heart team should agree on an estimated 30-day
mortality risk for each patient based upon integrating a
careful clinical assessment and utilizing appropriate risk
prediction scoring systems, preferably the STS score. Sur-
gical mortality risk strata are difficult to precisely assign, but
an estimated 30-day mortality of 4% is considered low
risk, 4–10% is intermediate risk, 10% is high risk, and
15% is very high risk. A patient is considered at extreme
risk if at least two cardiovascular surgeons from a tertiary
centre of excellence deny surgery because of prohibitive
operative risks, estimated to be a combined 50% risk of
irreversible morbidity or mortality (13). In addition to the
specific risk factors that can prohibit patients from under-
going TAVI or surgical aortic valve replacement (SAVR)
(Table 1), the operative risk assessment is also important to
identify patients who are likely not to benefit from either
TAVI or SAVR (the so-called ‘futility’ category of high-risk
patients). An expected improvement in the quality of life
(QOL) may further be necessary to identify treatment
responders vs. non- responders. Individualized life expec-
tancy assumptions should be incorporated by the heart team
in the clinical decision-making process as a central factor in
weighing the risk-benefit ratio. Prognostic indices of life
expectancy may play a central role in moving beyond
arbitrary age-based cut-offs (14).Posterior Table of Sternum
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customized management decisions for common and unusual
clinical scenarios in terms of patient selection, procedural
performance, and complication management. An example is
the frequent situation of severe AS and concomitant coro-
nary artery disease (CAD). The complexity of CAD and
appropriate revascularization strategies in the setting of
AS should be determined by consensus from interven-
tional cardiologists and cardiovascular surgeons (15,16)
In new TAVI clinical trials, angiographic risk scores (e.g.
SYNTAX score) may be utilized to help determine the
complexity of CAD, as a basis for the inclusion in the trial.
hresholds for coronary revascularization and the choice for a
taged or concomitant PCI with TAVI should be guided by
he complexity of the CAD and other factors as determined
y the heart team (17,18). In general, the plan to deal with
other co-existing conditions [such as atrial fibrillation
(AF), other valvular lesions, and other congenital lesions]
should be pre-specified and all complications encoun-
tered in the treatment of associated conditions (including
treatment after the TAVI procedure) should be captured.
Such thorough pre-procedural assessment is also valuable
in discriminating new post-procedural complications from
simple exacerbations of pre-existing conditions.
Clinical Endpoints
Mortality
In addition to the original VARC definitions, VARC-2
recommends the collection of immediate procedural mortality
o capture intra-procedural events that result in immediate
r consequent death 72 h post-procedure. Taking into
account the surgical literature, procedural mortality consists
f all-cause mortality within 30 days or during index
rocedure hospitalization—if the postoperative length of
tay is longer than 30 days.
The cause of death should be captured, based on a careful
eview of narrative summaries and source material. All-
ause, cardiovascular, and non-cardiovascular mortality
hould be reported after 30 days during the follow-up
Table 2). In determining the cause of death, the adjudica-
ion committee should consider the clinical context at the
ime of the index procedure and during the time interval
eading up to death. All efforts (including the use of national
eath registries) should be made to identify, precisely
haracterize, and appropriately classify any death.
yocardial Infarction
yocardial injury as determined by a significant rise in
ardiac biomarkers occurs frequently following TAVI, and a
ignificant magnitude of myocardial injury has been associ-
ted with worse outcomes (19). Valve Academic Research
onsortium-2 recommends the systematic collection of
iomarkers of myocardial injury prior to the procedure,
ithin 12–24 h after the procedure, at 24 h thereafter, at
2 h or at discharge, and, if still elevated, daily until valuesshow a decline. Similar to the previous VARC recommen-
dations, the definition of peri-procedural (72 h following
TAVI) MI will be based on a combination of clinical criteria
and cardiac biomarkers. However, the threshold values have
been adjusted (Table 3). Acute ischemic events occurring
after 72 h should be considered spontaneous myocardial
infarctions and defined in accordance with the universal MI
guidelines (20).
Stroke
With increasing attention to stroke as an important peri-
procedural complication of TAVI (21), the FDA has
emphasized the need for an accurate assessment of stroke
and has participated actively in recommending specific
details of the VARC-2 definitions. In an attempt to further
align with the fundamental definitions now endorsed by the
FDA (22), consensus was reached at VARC-2 to further
refine the definition of stroke and recommend the use of
these definitions in future TAVI clinical trials (Table 4).
The definitions endorsed by the FDA are intended to apply
to a wide range of clinical trials and to enable those trials to
assess the clinically relevant consequences of vascular brain
injury for determining the safety or effectiveness of an
intervention.
Stroke is defined as an acute episode of focal or global
neurological dysfunction caused by the brain, spinal cord, or
retinal vascular injury as a result of hemorrhage or infarc-
tion. Stroke may be classified as ischemic or hemorrhagic
with appropriate subdefinitions. Ischemic stroke is defined
as an acute episode of focal cerebral, spinal, or retinal
dysfunction caused by infarction of central nervous system
tissue. Hemorrhagic stroke is defined as an acute episode of
focal or global cerebral or spinal dysfunction caused by
intraparenchymal, intraventricular, or subarachnoid hemor-
rhage. A stroke may be classified as ‘undetermined’ if there
is insufficient information to allow the categorization as
MortalityTable 2 Mortality
All-cause mortality
Cardiovascular mortality
Any of the following criteria:
Death due to proximate cardiac cause (e.g. myocardial infarction,
cardiac tamponade, worsening heart failure)
Death caused by non-coronary vascular conditions such as neurological events,
pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or
other vascular disease
All procedure-related deaths, including those related to a complication of the
procedure or treatment for a complication of the procedure
All valve-related deaths including structural or non-structural valve dysfunction
or other valve-related adverse events
Sudden or unwitnessed death
Death of unknown cause
Non-cardiovascular mortality
Any death in which the primary cause of death is clearly related to another
condition (e.g. trauma, cancer, suicide)ischemic or hemorrhagic.
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be assessed is a transient ischemic attack (TIA). Transient
ischemic attack is defined as a transient episode of focal
neurological dysfunction caused by the brain, spinal cord, or
retinal ischemia, without acute infarction. The difference
between TIA and ischemic stroke is the presence of tissue
damage on neuro-imaging studies or new sensory-motor
deficit persisting 24 h. By definition, a TIA does not
produce a lasting disability.
Valve Academic Research Consortium-2 recognizes that
an assessment of stroke is incomplete without an appropri-
ate measurement of the disability resulting from the stroke.
Valve Academic Research Consortium-2 recommends the
use of the modified Rankin Scale (mRS) to assess this
clinical disability (23–25). The assessment of the mRS
should occur at all scheduled visits in a trial and at 90 days
after the onset of any stroke. This approach will maximize
the detection of new or recurrent strokes, assist in the
ongoing evaluation of events previously determined as
TIAs, and provide an accepted and reliable indicator of the
long-term impact of a given stroke.
Previously, VARC recommended categorizing strokes as
‘major’ and ‘minor’ based upon mRS scores. To enhance the
accuracy in the description of a given stroke and to provide
accurate categorization of strokes within a given trial,
VARC-2 now recommends the use of the terms ‘disabling’
Myocardial InfarctionTable 3 Myocardial Infarction
Peri-procedural MI (72 h after the index procedure)
New ischemic symptoms (e.g. chest pain or shortness of breath), or new
ischemic signs (e.g. ventricular arrhythmias, new or worsening heart failure,
new ST-segment changes, hemodynamic instability, new pathological Q-
waves in at least two contiguous leads, imaging evidence of new loss of
viable myocardium or new wall motion abnormality) AND
Elevated cardiac biomarkers (preferable CK-MB) within 72 h after the index
procedure, consisting of at least one sample post-procedure with a peak
value exceeding 15 x as the upper reference limit for troponin or 5 x for
CK-MB.* If cardiac biomarkers are increased at baseline (99th
percentile), a further increase in at least 50% post-procedure is required
AND the peak value must exceed the previously stated limit
Spontaneous MI (72 h after the index procedure)
Any one of the following criteria
Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at
least one value above the 99th percentile URL, together with the evidence
of myocardial ischemia with at least one of the following:
Symptoms of ischemia
ECG changes indicative of new ischemia [new ST-T changes or new left
bundle branch block (LBBB)]
New pathological Q-waves in at least two contiguous leads
Imaging evidence of a new loss of viable myocardium or new wall
motion abnormality
Sudden, unexpected cardiac death, involving cardiac arrest, often with
symptoms suggestive of myocardial ischemia, and accompanied by
presumably new ST elevation, or new LBBB, and/ or evidence of fresh
thrombus by coronary angiography and/or at autopsy, but death occurring
before blood samples could be obtained, or at a time before the
appearance of cardiac biomarkers in the blood.
Pathological findings of an acute myocardial infarction
*Previously in the original VARC it was 10 and 5 for troponin and CK-MB, respectively.and ‘non-disabling.’ A disabling stroke is one that results (at90 days after stroke onset) in an mRS score of 2 and an
increase in 1 mRS category from an individual’s pre-
stroke baseline. A non-disabling stroke is one that results (at
90 days after stroke onset) in an mRS score of 2 or that
does not result in an increase in 1 mRS category from an
individual’s pre-stroke baseline. In addition to this catego-
rization of disabling and non-disabling strokes, the end-
point of all strokes should be reported.
Although brain imaging (typically, MRI for acute and
chronic ischemia and hemorrhage, and CT for acute and
chronic hemorrhage and chronic ischemia) is often used to
supplement the clinical diagnosis of stroke (26), a diagnosis of
stroke may be made on clinical grounds alone. Valve Academic
Research Consortium-2 recognizes that stroke symptoms are
protean and not well suited to a pre-specified itemized listing.
Accordingly, VARC-2 recommends that a vascular neurologist
experienced in clinical trials involving stroke be included in all
phases of trial planning, execution, and monitoring, including
involvement in the Clinical Events Committee and the Data
and Safety Monitoring Board.
New insights into the timing of events show delayed or
late occurrence of strokes, beyond the early post-implantation
Stroke and TIATable 4 Stroke and TIA
Diagnostic criteria
Acute episode of a focal or global neurological deficit with at least one of the
following: change in the level of consciousness, hemiplegia, hemiparesis,
numbness, or sensory loss affecting one side of the body, dysphasia or
aphasia, hemianopia, amaurosis fugax, or other neurological signs or
symptoms consistent with stroke
Stroke: duration of a focal or global neurological deficit 24 h; OR 24 h if
available neuroimaging documents a new haemorrhage or infarct; OR
the neurological deficit results in death
TIA: duration of a focal or global neurological deficit 24 h, any variable
neuroimaging does not demonstrate a new hemorrhage or infarct
No other readily identifiable non-stroke cause for the clinical presentation (e.g.
brain tumour, trauma, infection, hypoglycemia, peripheral lesion,
pharmacological influences), to be determined by or in conjunction with
the designated neurologist*
Confirmation of the diagnosis by at least one of the following:
Neurologist or neurosurgical specialist
Neuroimaging procedure (CT scan or brain MRI), but stroke may be
diagnosed on clinical grounds alone
Stroke classification
Ischemic: an acute episode of focal cerebral, spinal, or retinal dysfunction
caused by infarction of the central nervous system tissue
Hemorrhagic: an acute episode of focal or global cerebral or spinal dysfunction
caused by intraparenchymal, intraventricular, or subarachnoid
hemorrhage
A stroke may be classified as undetermined if there is insufficient information
to allow categorization as ischemic or haemorrhagic
Stroke definitions†
Disabling stroke: an mRS score of 2 or more at 90 days and an increase in at
least one mRS category from an individual’s pre-stroke baseline
Non-disabling stroke: an mRS score of 2 at 90 days or one that does not
result in an increase in at least one mRS category from an individual’s
pre-stroke baseline
*Patients with non-focal global encephalopathy will not be reported as a stroke without unequiv-
ocal evidence of cerebral infarction-based upon neuroimaging studies (CT scan or Brain MRI).
†Modified Rankin Scale assessments should be made by qualified individuals according to a
certification process (23–25).
mRS  modified Rankin Scale.
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additionally related to other factors or patient susceptibili-
ties and should necessitate active investigation of devices
and adjunctive pharmacotherapy to reduce the frequency
and severity of strokes after TAVI, including precise docu-
mentation of the use and dosage of antithrombotic and
antiplatelet medication. Patient baseline characteristics (e.g.
carotid stenosis) and postoperative complications (e.g. AF)
need to be carefully documented to be able to identify the
contributing causes of stroke.
Invasive stroke management (catheter-based intracranial
intervention) is gaining an increasingly important role and
may impact morbidity and mortality. Valve Academic Re-
search Consortium-2 therefore recommends the ascertain-
ment of any acute stroke management strategy (e.g. aspira-
tion, thrombolysis, or conservative management).
Bleeding Complications
Valve Academic Research Consortium-2 acknowledges the
fact that the Bleeding Academic Research Consortium
(BARC) recently convened and established standardized
bleeding definitions for patients receiving antithrombotic
therapy and undergoing coronary revascularization (PCI or
CABG) (28,29). However, because the current definitions
have been well adopted and shown to be accurate in
predicting adverse events (30), VARC-2 has chosen to
maintain the original VARC definitions with BARC clas-
sifications (Table 5), recognizing that future validation of
BARC criteria in this population may warrant revision of
the current recommendations.
With respect to blood transfusions, it is critical to
acknowledge that a bleeding complication has to be the
result of overt bleeding and cannot be adjudicated based on
BleedingTable 5 Bleeding
Life-threatening or disabling bleeding
Fatal bleeding (BARC type 5) OR
Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or
pericardial necessitating pericardiocentesis, or intramuscular with
compartment syndrome (BARC type 3b and 3c) OR
Bleeding causing hypovolaemic shock or severe hypotension requiring
vasopressors or surgery (BARC type 3b) OR
Overt source of bleeding with drop in haemoglobin 5 g/dL or whole blood or
packed red blood cells (RBCs) transfusion 4 units* (BARC type 3b)
Major bleeding (BARC type 3a)
Overt bleeding either associated with a drop in the hemoglobin level of at least
3.0 g/dl or requiring transfusion of two or three units of whole blood/RBC, or
causing hospitalization or permanent injury, or requiring surgery AND
Does not meet criteria of life-threatening or disabling bleeding
Minor bleeding (BARC type 2 or 3a, depending on the severity)
Any bleeding worthy of clinical mention (e.g. access site hematoma) that does
not qualify as life-threatening, disabling, or major
*Given that one unit of packed RBC typically will raise the hemoglobin concentration by 1 g/dl, an
estimated decrease in hemoglobin will be calculated.
BARC  Bleeding Academic Research Consortium (29); RBC  red blood cell.blood transfusions alone.Acute Kidney Injury
The original VARC definitions recommended the use of a
modified version of the RIFLE classification. However, we
now recommend using the AKIN system (Table 6), which
is a modified version of RIFLE that has been adopted by many
in the nephrology community, including the KDIGO initia-
tive (31,21). As a result, acute kidney injury (AKI) can also be
diagnosed according to urine output measures (Table 6).
In comparison with the original VARC, the timing for
the diagnosis of AKI is extended from 72 h to 7 days.
Patients who experience AKI should have follow-up renal
function assessments after 7 days until stabilization.
Vascular Complications
Table 7 lists VARC-2 definitions for major and minor
vascular complications. Further clarifications of these defi-
nitions to supplement the original VARC document are as
follows. Pre-planned surgical access or a planned endovas-
cular approach to vascular closure (e.g. ‘pre- closure’) (33,34)
should be considered as part of the TAVI procedure and not
as a complication, unless untoward clinical consequences are
documented (e.g. bleeding complications, limb ischemia,
distal embolization, or neurological impairment). Un-
planned endovascular stenting or surgical repair for any
vascular complications during the index procedure without
other clinical sequelae should be considered a minor vascular
complication, except if associated with qualifying conse-
quences (Table 7). Complications related to alternative
access sites, including the left-ventricular apex, subclavian
artery, or aorta should be systematically recorded. To ensure
accurate capture of these elements, VARC-2 strongly rec-
ommends that detailed information regarding the access site
and pre-planned vascular closure technique be recorded as
well as the use of any additional unplanned access or closure
techniques (surgical repair, endovascular stenting, or endo-
vascular balloon therapy). Since many vascular complica-
tions will also result in a bleeding complication, events that
meet VARC-2 definitions for both categories should be
Acute Kidney Injury (AKIN Classification*)Table 6 Acute Kidney Injury (AKIN Classification*)
Stage 1
Increase in serum creatinine to 150–199% (1.5–1.99 x increase compared
with baseline) OR increase of 0.3 mg/dl (26.4 mmol/l) OR
Urine output 0.5 ml/kg/h for 6 but 12 h
Stage 2
Increase in serum creatinine to 200–299% (2.0–2.99  increase compared
with baseline) OR
Urine output 0.5 ml/kg/h for 12 but 24 h
Stage 3†
Increase in serum creatinine to 300% (3  increase compared with
baseline) OR serum creatinine of 4.0 mg/dl (354 mmol/l) with an
acute increase of at least 0.5 mg/dl (44 mmol/l) OR
Urine output 0.3 ml/kg/h for 24 h OR
Anuria for  12 hThe increase in creatinine must occur within 48 h. *Mehta et al. (31). †Patients receiving renal
replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria.
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that all vascular complications be recorded as either access
(e.g. iliac rupture) or non-access site-related (e.g. ascending
aorta dissection or rupture unless aortic access is used and
the event originates from the cannulation site).
Conduction Disturbances and Arrhythmias
Valve Academic Research Consortium-2 proposes the sys-
tematic collection of data on the frequency of implant-
related new and/or worsened conduction disturbances and
Vascular Access Site andAccess-Relat d ComplicationsTable 7 Vascular A cess Site andAccess-Related Complications
Major vascular complications
Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation,
or new apical aneurysm/pseudo-aneurysm OR
Access site or access-related vascular injury (dissection, stenosis, perforation,
rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible
nerve injury, compartment syndrome, percutaneous closure device failure)
leading to death, life-threatening or major bleeding*, visceral ischemia, or
neurological impairment OR
Distal embolization (non-cerebral) from a vascular source requiring surgery or
resulting in amputation or irreversible end-organ damage OR
The use of unplanned endovascular or surgical intervention associated with
death, major bleeding, visceral ischemia or neurological impairment OR
Any new ipsilateral lower extremity ischemia documented by patient
symptoms, physical exam, and/or decreased or absent blood flow on lower
extremity angiogram OR
Surgery for access site-related nerve injury OR
Permanent access site-related nerve injury
Minor vascular complications
Access site or access-related vascular injury (dissection, stenosis, perforation,
rupture, arterio-venous fistula, pseudoaneuysms, hematomas,
percutaneous closure device failure) not leading to death, life-threatening
or major bleeding*, visceral ischemia, or neurological impairment OR
Distal embolization treated with embolectomy and/or thrombectomy and not
resulting in amputation or irreversible end-organ damage OR
Any unplanned endovascular stenting or unplanned surgical intervention not
meeting the criteria for a major vascular complication OR
Vascular repair or the need for vascular repair (via surgery, ultrasound-guided
compression, transcatheter embolization, or stent-graft)
Percutaneous closure device failure
Failure of a closure device to achieve hemostasis at the arteriotomy site
leading to alternative treatment (other than manual compression or
adjunctive endovascular ballooning)
*Refers to VARC bleeding definitions.
Conduction Disturbances and ArrhythmiasTable 8 Conduction Disturbances and Arrhythmias
Up to 72 h, continuous rhythm monitoring is recommended in order to maximize t
Data elements to be collected should include
Baseline conduction abnormalities, paroxysmal or permanent atrial fibrillation (or
Implant-related new or worsened cardiac conduction disturbance (new or worsene
third-degree AV block, incomplete right bundle branch block, right bundle bran
fascicular block, or left posterior fascicular block, including block requiring a p
Persistent or transient high-degree AV block. High-grade AV block is persistent if i
New permanent pacemaker implantation, with precision of the indication and the
New-onset atrial fibrillation (or flutter)†
Any new arrhythmia resulting in hemodynamic instability or requiring therapy‡
*Type of permanent pacemaker should be recorded (e.g. defibrillator, single vs. dual chamber, biv
that has the ECG characteristics of atrial fibrillation (or flutter) and lasts sufficiently long to be recorded on a
or initiation of a new medication (oral anticoagulation, rhythm, or rate controlling therapy).the incidence and indication for permanent pacemaker
implantation (Table 8). In addition, the frequency of spe-
cific arrhythmias following TAVI should be recorded as
they may result in prolonged hospitalization and impaired
clinical outcomes. New-onset AF (or flutter) is diagnosed as
any arrhythmia within hospitalization that has the ECG
characteristics of AF and lasts sufficiently long to be
recorded on a 12-lead ECG, or for at least 30 s on a rhythm
strip (35). The therapeutic approach to new-onset AF
(spontaneous conversion, electrical or medical cardioversion,
initiation of oral anticoagulation, and rate or rhythm control
medications) and any clinical consequences should be thor-
oughly documented in the case report form.
Other TAVI-Related Complications
The original VARC document recommended the collection
of a number of TAVI-related complications, but did not
provide specific endpoint definitions for several endpoints.
Valve Academic Research Consortium-2 recommends re-
porting any other complications related to the TAVI pro-
cedure, even those occurring less frequently, and provides
formal VARC-2 definitions (Table 9) (36–38).
Additional Considerations
For studies or trials where the occurrence, prevention, or
treatment of cerebral infarction is a fundamental feature
(e.g. embolic protection devices) additional appropriate
imaging in all or a subset of patients may be necessary to
allow determination of effectiveness.
Valvular Function
Valve Academic Research Consortium-2 maintains the
original recommendations to use echocardiography as the
primary imaging modality for the assessment of prosthetic
valve function (39). This should include the valve position,
morphology, function, and evaluation of the left ventricle
(LV) and right ventricle (RV) size and function. The
suggested time points for routine follow-up transthoracic
echocardiography (TTE) following valve implantation are:
immediately (before discharge) following the implantation
for transarterial approaches or within 30 days for transapical
ection of arrhythmias
), and the presence of permanent pacemaker*
-degree atrioventricular (AV) block, second-degree AV block (Mobitz I or Mobitz II),
k, intraventricular conduction delay, left bundle branch block, left anterior
ent pacemaker implant
sent every time the underlying rhythm is checked
er of days post-implant of the placement of new permanent pacemaker
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1 year following implantation, and yearly thereafter. At
these endpoints, prosthetic aortic valve stenosis and regur-
gitation should be reported.
Transcatheter Valve Stenosis
The assessment of prosthetic valve stenosis should be an
integrative process utilizing multiple parameters of valve
function. Table 10 outlines the primary parameters used for
assessing prosthetic valve function based on published
guidelines (40). Divergence from the guidelines is based on
a number of studies (41,42), as well as methods used in large
randomized control trials of TAVI (43,44). In addition,
VARC-2 does not recommend using acceleration time,
which is dependent on ventricular function and heart rate
(42). The limitation of flow-dependent parameters such as
peak jet velocity or mean transprosthetic gradient is obvious,
however, even flow-independent parameters such as the
effective orifice area (EOA) and the Doppler velocity index
(DVI) have limitations: (i) the absolute EOA does not
account for the cardiac output requirements in relation to
Other TAVI-Related ComplicationsTable 9 Other TAVI-Related Complications
Conversion to open surgery
Conversion to open sternotomy during the TAVI procedure secondary to any proce
Unplanned use of cardiopulmonary bypass (CPB)
Unplanned use of CPB for hemodynamic support at any time during the TAVI proc
Coronary obstruction
Angiographic or echocardiographic evidence of a new, partial or complete, obstru
calcifications, or dissection, occurring during or after the TAVI procedure
Ventricular septal perforation
Angiographic or echocardiographic evidence of a new septal perforation during or
Mitral valve apparatus damage or dysfunction
Angiographic or echocardiographic evidence of new damage (chordae papillary m
to the THV) of the mitral valve during or after the TAVI procedure
Cardiac tamponade
Evidence of a new pericardial effusion associated with hemodynamic instability a
Endocarditis
Any one of the following:
Fulfillment of the Duke endocarditis criteria*
Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as second
Findings of abscess, pus, or vegetation involving a repaired or replaced valve du
Valve thrombosis
Any thrombus attached to or near an implanted valve that occludes part of the bl
Note that valve-associated thrombus identified at autopsy in a patient whose c
Valve malpositioning
Valve migration
After initial correct positioning, the valve prosthesis moves upwards or downwa
Valve embolization
The valve prosthesis moves during or after deployment such that it loses conta
Ectopic valve deployment
Permanent deployment of the valve prosthesis in a location other than the aort
TAV-in-TAV deployment
An additional valve prosthesis is implanted within a previously implanted prosthe
procedure
*Durack et al. (72).
TAVI  transcatheter aortic valve implantation; THV  transcatheter heart valve.the patient’s body size; thus lower criteria should be used to adefine prosthetic valve stenosis in patients with BSA 1.6
m2 (Table 10), (ii) the indexed EOA may overestimate the
alve-related hemodynamic burden in obesity; hence, lower
riteria may be more appropriate in patients with a body
ass index 30 kg/m2, (iii) DVI severity criteria are
ependent on the left ventricular outflow tract (LVOT)
ize; thus a lower threshold may be more appropriate in
atients with LVOT diameters of 25 mm. The EOA
hould generally be calculated with the use of the LVOT
iameter and the velocity measured just underneath the
pical margin of the valve stent (45,46). In cases where the
anding zone of the stent is low in the LVOT, the diameter
nd velocity may both be measured in the proximal portion
f the stent. Unlike the surgically implanted valve, the
ranscatheter prosthetic valve EOA is defined not only by
he size of the valve but also by the patient’s aortic valve/
nnular anatomy and procedural variables. Thus, well-
stablished normal transcatheter valve gradients and EOAs
ased on pre-implant aortic annular dimensions do not
urrently exist. Clinicians should be aware of this variability
hen assessing a patient for transcatheter valve function
lated complications
f a coronary ostium, either by the valve prosthesis itself, the native leaflets,
the TAVI procedure
or to the leaflet) to the mitral valve apparatus or dysfunction (e.g. restrictions due
rly related to the TAVI procedure
infection by histological or bacteriological studies during a re-operation
n autopsy
w path, interferes with valve function, or is sufficiently large to warrant treatment.
f death was not valve-related should not be reported as valve thrombosis
thin the aortic annulus from its initial position, with or without consequences
the aortic annulus
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serial comparisons.
The assessment of transcatheter valve dysfunction in-
cludes the immediate post-TAVI hemodynamics and the
follow-up evaluation. The immediate post-TAVI evalua-
tion documents initial valve appearance (position and cir-
cularity of the stent, and leaflet morphology and motion)
and a comprehensive hemodynamic evaluation. Valve Aca-
demic Research Consortium-2 advocates using the integra-
tive approach outlined in the algorithm shown in Figure 4 as
part of a comprehensive hemodynamic evaluation by ini-
tially using one flow dependent (e.g. mean gradient) and
one flow independent criterion (e.g. EOA) for the initial
hemodynamic evaluation. If there is discordance between
these measurements, then the DVI should be calculated. An
abnormal DVI indicates possible prosthetic valve dysfunc-
tion. A normal DVI indicates intrinsically normal prosthetic
valve function, and the indexed EOA can then be used to
determine the reason for the initial measurement discor-
dance. When the indexed EOA is low in the setting of a
normal DVI, the patient probably has a prosthesis-patient
mismatch (PPM), an indicator of the intrinsic relationship
of the implanted valve to the cardiac output requirements of
the patient (47). Prosthesis-patient mismatch occurs in the
Prosthetic Valve DysfunctionTable 10 Prosthetic Valve Dysfunction
Nor
Quantitative parameters (flow-dependent)†
Peak velocity (m/s) 3 m
Mean gradient (mmHg) 20 m
Quantitative parameters (flow-independent)
Doppler velocity index‡ 0.35
Effective orifice aread§ 1.1
Effective orifice area 0.9
Insign
Indexed effective orifice area¶ (cm2/m2) 0.85
Indexed effective orifice area# (cm2/m2) 0.70
M
Semi-quantitative parameters
Diastolic flow reversal in the
descending aorta—PW
Absent or brie
Circumferential extent of prosthetic
valve paravalvular regurgitation (%)**
1
Quantitative parameters‡
Regurgitant volume (mL/beat) 3
Regurgitant fraction (%) 3
EROA (cm2)
*In conditions of normal or near normal stroke volume (50–70 ml).
regurgitation. ‡For LVOT 2.5 cm, significant stenosis criteria is 0.2
and the size of the native annulus). Use in setting of BSA1.6 cm2. ¶U
well-validated and may overestimate the severity compared with the
EROA  effective regurgitant orifice area; PW  pulsed wave.setting of a morphologically normal valve and is considered nto be hemodynamically insignificant if the indexed EOA is
0.85 cm2/m2, moderate if between 0.65 and 0.85 cm2/m2,
and severe if 0.65 cm2/m2. However, for obese patients
body mass index 30 kg/m2) lower criteria may be more
ppropriate (Table 10).
ranscatheter Valve Regurgitation
here is growing evidence suggesting a significant associa-
ion of post-procedural paravalvular aortic regurgitation
AR) with short- and long- term mortality (48,49). As the
uration of implanted transcatheter heart valves increases,
alve durability and dysfunction become more crucial issues.
valuating the presence and severity of regurgitation should
nclude an assessment of both central and paravalvular
omponents, with a combined measurement of ’total’ aortic
egurgitation (AR) reflecting the total volume load imposed
n the LV (Table 10). The quantitative and semi-quantitative
emodynamic assessment of AR severity should be per-
ormed with Doppler echocardiography according to the
uidelines (39,50,51). Color Doppler evaluation should be
erformed just below the valve stent for paravalvular jets,
nd at the coaptation point of the leaflets for central
egurgitation. Although all imaging windows should be used,
he parasternal short-axis view is critical in assessing the
Prosthetic Aortic Valve Stenosisa
Mild Stenosis Moderate/Severe Stenosis
3–4 m/s 4 m/s
20–40 mm Hg 40 mm Hg
0.35–0.25 0.25
1.1–0.8 cm2 0.8 cm2
0.9–0.6 cm2 0.6 cm2
Prosthesis-Patient Mismatch (PPM)
t Moderate Severe
2 0.85–0.65 cm2/m2 0.65 cm2/m2
2 0.90–0.60 cm2/m2 0.60 cm2/m2
rosthetic Aortic Valve Regurgitation
Moderate Severe
diastolic Intermediate Prominent, holodiastolic
10–29% 30%
30–59 ml 60 ml
30–49% 50%
2 0.10–0.29 cm2 0.30 cm2
parameters are more affected by flow, including concomitant aortic
in setting of BSA 1.6 cm2 (note: dependent on the size of the valve
etting of BMI30 kg/cm2. #Use in setting of BMI30 kg/cm2. **Not
tive Doppler.mal
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tive regurgitant orifice area, and regurgitant fraction (Table 10)
should be performed (40,51,52). The regurgitant volume may
be calculated as the difference between the stroke volume across
any non-regurgitant orifice (RVOT or mitral valve) and the
stroke volume across the LVOT.
It is important to realize that at this time the body of
evidence supporting the numerical criteria used in Table
0 as well as Figure 4 may be limited. These criteria
should be used as guidelines for clinical decision-making
and require further validation as our experience continues
to expand.
Follow-Up Assessments
The follow-up assessment should also begin with valve
imaging and documentation of changes in morphology.
When determining whether a patient has developed hemo-
dynamically significant structural valve failure, the patient’s
own baseline echocardiographic parameters should be used
as a reference. An increase in the mean gradient10 mm Hg, a
decrease in the EOA 0.3–0.4 cm2, or a reduction in the
VI 0.1–0.13 probably indicates a change in valve func-
ion and should trigger a comprehensive hemodynamic
Figure 4 Transcatheter Heart Valve Haemodynamic Evaluationvaluation. Whenever valve dysfunction is suspected, the aareful evaluation of valve morphology should confirm a
tructurally abnormal valve. In addition, measurement error
ust be excluded; the use of a consistent LVOT diameter
or more accurate follow-up study comparisons is recom-
ended. Finally, changes in ventricular morphology would
e expected in the setting of long-standing significant
alvular dysfunction and this parameter may support the
linical assessment of severity.
Although the rate of moderate or severe regurgitation
ay appear to be less at the follow-up, this may be the result
f attrition of the sickest patients. To assess such time
rends, it is recommended to report an individual patient’s
rogression of regurgitation, in a table that provides changes
etween short-term and long-term regurgitation, including
ortality (48).
uality of Life
uality of Life Evaluation in Aortic Stenosis
ew York Heart Association (NYHA) classification is
imited by the discrete nature of the scale, which provides
nly modest resolution to detect clinically relevant
hanges. Moreover, since the NYHA class is assessed by
ithmn external body rather than the patient, it does not
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more properly considered a measure of the functional
status than the QOL.
The Minnesota Living with Heart Failure Questionnaire
(MLHF) (53) and the Kansas City Cardiomyopathy Ques-
tionnaire (KCCQ) (54,55) have a number of desirable
properties for the evaluation of health-related QOL
(HRQOL) in the setting of AS. Both instruments produce
outcomes on a continuous scale, which improves respon-
siveness and sensitivity. Although only the MLHF has been
specifically validated in patients with aortic valve disease
(56), preliminary experience with the KCCQ in patients
undergoing TAVI has also demonstrated a high degree of
responsiveness and internal consistency (57).
Recommended Endpoints and Timing of Assessment
Valve Academic Research Consortium-2 recommends that
a comprehensive assessment of HRQOL for patients un-
dergoing TAVI incorporate both a heart failure-specific
measure (such as the KCCQ or MLHF) as well as one or
more generic measures [such as the Medical Outcomes
Study Short-Form 36 (SF-36), the Short-Form 12 (SF-12),
or the EuroQOL (EQ-5D)] (58–60). The disease-specific
measures offer improved sensitivity/responsiveness as well as
clinical interpretability, whereas the inclusion of a generic
health status measure is useful because it captures some
additional domains. Furthermore, generic measures can
enhance the comparability across different diseases and
populations and can be used to compare patients with
population-level benchmarks.
For the comparison of TAVI vs. SAVR (or for the
comparison of alternative access sites for TAVI), we rec-
ommend that early QOL assessment be performed at 2
weeks, 1 month, and 3 months using a combination of
generic instruments and pain scales (e.g. visual analogue
scale) to assess the early recovery process. The evaluation of
the QOL at an intermediate time point (e.g. 6 months)
could also be considered in order to confirm that QOL
recovery is complete by this stage. At later time points (1–5
years), the use of heart failure-specific instruments to
identify the consequences of long-term valve performance
may be more useful. Finally, the assessment of cognitive
function at later time points (1–5 years) may be valuable for
the comparison of surgical vs. catheter-based techniques,
although these endpoints generally require highly special-
ized and demanding neuropsychiatric testing (61). In con-
trast, for the comparison of alternative TAVI systems (as
may be expected in the near future), HRQOL assessment
should focus mainly on heart failure-specific endpoints at
intermediate and later time points (1–5 years), wherein
between-device differences in the hemodynamic perfor-
mance or structural valve deterioration may emerge. The
inclusion of disease-specific QOL measures in these studies
can also provide insight into the consequences of valve-
related complications such as the need for pacemaker
insertion.Additional Considerations
It is essential to ensure complete ascertainment of HRQOL at
each time point, as missing data cannot be retrieved retrospec-
tively and statistical adjustment techniques (e.g. multiple im-
putation) that assume that data are ’missing at random’ may
not be adequate. Differential mortality between two treatments
may complicate the interpretation of QOL results since the
QOL may appear to ’improve’ over time even with an ineffec-
tive therapy simply because of attrition of the sickest patients.
The use of categorical endpoints that characterize outcomes as
favorable (e.g. survival AND improvement of QOL endpoints)
(44,57) or endpoints that integrate survival and the QOL (e.g.
quality-adjusted life expectancy) may provide more interpreta-
ble results. In such cases, reporting the outcomes in both ways
(i.e. among the entire study cohort and separately among only
the surviving patients) will provide the most complete descrip-
tion of the results.
Composite Endpoints
Rationale and Caveats
Comparisons of the success, safety, and effectiveness with
achievable study cohort sample sizes may at times require
the use of composite endpoints. However, it is important that
composites contain components that have roughly similar
impacts on the patient. A family of single endpoints tending in
the same direction may, as a family of hypotheses, be statisti-
cally significant when individual endpoints are not.
Each post-procedural event has a different temporal risk
profile (hazard function) modulated by different risk factors.
Therefore, traditionally, the evaluation of the safety and
efficacy of procedures has focused on in-hospital events
(complications and morbidity), events within 30 days of the
procedure, and ‘late’ events.
Specific Composite Endpoints
The assessment of TAVI, SAVR, and their alternatives or
new devices should include device, procedure, and patient-
oriented endpoints. These endpoints have been devised to
be applicable to both TAVI and SAVR. Previous clinical
trials have used the all-cause mortality at 1 year as the
primary clinical endpoint. Owing to the emergence of stroke
as an important clinical event, future trials should also
require the composite of all-cause mortality and disabling
stroke as a primary or secondary endpoint.
The first VARC document proposed three composite
endpoints: device success, early safety, and clinical efficacy.
Valve Academic Research Consortium-2 goes beyond the
early and intermediate experience of TAVI, drawing upon
prior surgical AVR guidelines to include time-related safety
endpoints (62). Therefore, VARC-2 recommends a new
composite endpoint, time-related valve safety, which com-
bines valve dysfunction, endocarditis, and thrombotic com-
plications of the prosthesis (Table 11).
rgical a
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Although the original VARC standardized endpoint defi-
nitions were fundamentally useful and have been widely
adopted, growing experience with TAVI studies has iden-
tified some definitions as ambiguous, of limited clinical
utility, or in need of updating or extension (5,6,63,64). This
need provided the rationale for a VARC-2 document with
such improvements and additions. As was the case with the
original VARC process, it should be emphasized that this
consensus manuscript is not intended to be a guidelines
document, but rather a practical tool to facilitate and inform
clinical research in TAVI.
Current clinical trials are focusing more on intermediate
risk patients, and more studies are comparing TAVI with
surgical AVR. Therefore, it becomes increasingly important
to identify those patients who benefit from either treatment.
Specific risk categories have been defined to allow universal
clinical study designs and outcome comparisons.
Changes and additions that have been applied to improve
the interpretation of clinical endpoint definitions and provide
Composite EndpointsTable 11 Composite Endpoints
Device success
Absence of procedural mortality AND
Correct positioning of a single prosthetic heart valve into the proper anatomical lo
Intended performance of the prosthetic heart valve (no prosthesis- patient misma
moderate or severe prosthetic valve regurgitation*)
Early safety (at 30 days)
All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening bleeding
Acute kidney injury—Stage 2 or 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complication
Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)
Clinical efficacy (after 30 days)
All-cause mortality
All stroke (disabling and non-disabling)
Requiring hospitalizations for valve-related symptoms or worsening congestive he
NYHA class III or IV
Valve-related dysfunction (mean aortic valve gradient 20 mmHg, EOA 0.9-1.1
regurgitation*)
Time-related valve safety
Structural valve deterioration
Valve-related dysfunction (mean aortic valve gradient 20 mm Hg, EOA 0.9–
regurgitation*)
Requiring repeat procedure (TAVI or SAVR)
Prosthetic valve endocarditis
Prosthetic valve thrombosis
Thrombo-embolic events (e.g. stroke)
VARC bleeding, unless clearly unrelated to valve therapy (e.g. trauma)
*Refers to VARC definitions. †As a basis for calculation of ’days alive outside the hospital’ endpoint
disease requiring intervention or intensified medical management; clinical symptoms of CHF w
administration of IV diuresis or inotropic therapy, performance of aortic valvuloplasty, institution o
clear documentation of anginal symptoms AND no clinical evidence that angina was related to CA
the body surface area.
BAV  balloon aortic valvuloplasty; TAVI  transcatheter aortic valve implantation; SAVR  sufurther insights on TAVI-related outcomes are as follows: (i)risk stratification should be done by a dedicated ‘heart team’
and include other factors (e.g. frailty, porcelain aorta) beyond
the traditional risk scores, and should take into account
co-existing conditions; (ii) immediate procedural mortality has
been added to capture intra-procedural events that result in
immediate or consequent death; (iii) stroke ascertainment
requires the use of precise definitions, standardized assess-
ments, close collaboration with neurology experts including the
consideration of acute stroke management, and has been
re-categorized as non-disabling or disabling; (iv) detailed doc-
umentation of the etiology of strokes and concomitant thera-
pies is needed to provide insights into the multi-factorial nature
of acute, early, and late strokes; (v) closure device failure is now
a separate category within vascular complications, and if
unplanned percutaneous or surgical intervention does not lead
to adverse outcomes, these are not considered as a major vascular
complication per se; (vi) the time for AKI diagnosis has been
extended from 72 h to 7 days; (vii) AKI is diagnosed
according to AKIN guidelines, which include classification
by the urine output to detect a wider range of etiologies;
AND
nd mean aortic valve gradient 20 mmHg or peak velocity 3 m/s, AND no
ure‡
nd/or DVI 0. 35 m/s, AND/OR moderate or severe prosthetic valve
2‡ and/or DVI 0.35 m/s, AND/ OR moderate or severe prosthetic valve
ementary appendix of Leon et al. (43) Includes heart failure, angina, or syncope due to aortic valve
ctive signs including pulmonary oedema, hypoperfusion, or documented volume overload AND
anical support (IABP or ventilation for pulmonary oedema) or haemodialysis for volume overload;
CS; documented loss of consciousness not related to seizure or tachyarrhythmia. ‡Depending on
ortic valve replacement.cation
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has changed from 10 ULN to 15 ULN based on recent
data (19); (ix) assessment of conduction disturbances and
arrhythmias has been reinforced (65–68); (x) new defini-
tions for several TAVI-related complications and valve
malpositioning are reported; (xi) echocardiography param-
eters of prosthetic valve stenosis and regurgitation have been
updated and now include the assessment of the prosthesis-
patient mismatch; (xii) for the QOL assessment, VARC-2
recommends the use of both heart failure-specific and
generic measures during the follow-up between 30 days and
5 years to fully assess the impact of the procedure and the
durability of clinical benefit. These definitions can be used
in studies comparing TAVI to surgical AVR, as well as in
future trials comparing first generation to next generation
TAVI devices.
The composite endpoint of device success has specifically
been criticized for being too strict with regard to valve
performance; for example, an AVA 1.2 cm2 seems unach-
evable in patients with smaller body habitus (5). The current
ARC-2 definition therefore corrects for the body surface area
o that valve performance is now assessed through the indexed
OA. It is notable that valve-in-valve procedures for failing
ioprostheses will frequently have a low device success, even
ith this modified definition (69). Considering that stroke has
merged as an important concern, the composite of all-cause
ortality and disabling stroke should be considered as a
rimary or secondary endpoint in future trials. Two ongoing
arge randomized trials [PARTNER II (NCT01314313) and
URTAVI (NCT01586910)] are already incorporating these
omposite endpoints.
With longer follow-up duration, it becomes more critical to
nclude time-related valve safety composite endpoints. This
ill eventually provide linearized rates of complications with
ranscatheter valves, known as ‘objective performance criteria’,
s has been used to evaluate surgical valves (70).
With this VARC-2 document, we have provided further
tandardization of endpoint definitions and hope that the
doption of these criteria will continue to increase, ulti-
ately leading to improved comparability and interpretabil-
ty of the study results.
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